Valter Torri

1986–2025 年に発表

156
論文数
36,566
被引用数
89
h 指数
154
i10 指数

被引用数

Valter Torri の年別被引用数1971 年: 被引用 2 件1973 年: 被引用 1 件1990 年: 被引用 1 件1991 年: 被引用 7 件1992 年: 被引用 5 件1993 年: 被引用 13 件1994 年: 被引用 2 件1995 年: 被引用 5 件1996 年: 被引用 9 件1997 年: 被引用 15 件1998 年: 被引用 25 件1999 年: 被引用 32 件2000 年: 被引用 49 件2001 年: 被引用 64 件2002 年: 被引用 85 件2003 年: 被引用 84 件2004 年: 被引用 102 件2005 年: 被引用 115 件2006 年: 被引用 120 件2007 年: 被引用 140 件2008 年: 被引用 144 件2009 年: 被引用 203 件2010 年: 被引用 236 件2011 年: 被引用 256 件2012 年: 被引用 293 件2013 年: 被引用 325 件2014 年: 被引用 316 件2015 年: 被引用 326 件2016 年: 被引用 268 件2017 年: 被引用 276 件2018 年: 被引用 229 件2019 年: 被引用 946 件2020 年: 被引用 1,148 件2021 年: 被引用 1,173 件2022 年: 被引用 863 件2023 年: 被引用 628 件2024 年: 被引用 1,039 件2025 年: 被引用 468 件2026 年: 被引用 10 件1972 年は被引用が無いため表示していません1974〜1989 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,102 件、この内訳の 19.6%中国: 引用元論文 1,581 件、この内訳の 10%イギリス: 引用元論文 1,471 件、この内訳の 9.3%イタリア: 引用元論文 1,468 件、この内訳の 9.2%ドイツ: 引用元論文 778 件、この内訳の 4.9%フランス: 引用元論文 731 件、この内訳の 4.6%カナダ: 引用元論文 630 件、この内訳の 4%オランダ: 引用元論文 572 件、この内訳の 3.6%日本: 引用元論文 546 件、この内訳の 3.4%スペイン: 引用元論文 537 件、この内訳の 3.4%オーストラリア: 引用元論文 516 件、この内訳の 3.2%スイス: 引用元論文 361 件、この内訳の 2.3%
0%19.6%その他 22.5%

分野

  • Medicine79.6%
  • Biochemistry, Genetics and Molecular Biology10.6%
  • Immunology and Microbiology4.1%
  • Health Professions0.9%
  • Engineering0.8%
  • Decision Sciences0.5%
  • その他3.5%

トピック

  • Cancer Immunotherapy and Biomarkers3.8%
  • Colorectal Cancer Treatments and Studies3.8%
  • Lung Cancer Treatments and Mutations3.5%
  • Lung Cancer Diagnosis and Treatment2.9%
  • Genetic factors in colorectal cancer2.5%
  • Ovarian cancer diagnosis and treatment2.4%
  • その他81.1%

共著者

全論文

検索で開く
  1. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2008 被引用: 2,670

  2. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

    著者: , , - Statistics in Medicine 1998 被引用: 4,831

  3. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 被引用: 1,009

  4. Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Saverio Minucci, Marco Foiani, Valter Daniel Longo, Giovanni Apolone, Valter Torri, Giancarlo Pruneri, Davide Bedognetti, Licia Rivoltini, Filippo de Braud - Cancer Discovery 2021 被引用: 302

  5. Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 被引用: 261

  6. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 1,126

  7. Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2010 被引用: 1,613

  8. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - ESMO Open 2020 被引用: 181

  9. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zoltán Takácsi Nagy, Ju‐Whei Lee, Catherine Fortpied, Jonathan Harris, Jean Bourhis, Anne Aupérin, Pierre Blanchard, Jean‐Pierre Pignon, David J. Adelstein, M. Alfonsi, Y. Belkacemi, Voichita Bar‐Ad, J. Bernier, Åse Bratland, G. Calais, Brittany Campbell, Jimmy J. Caudell, Sylvie Chabaud, Emmanuel Chamorey, Devendra Chaukar, Kwang Nam Choi, Olivier Choussy, Laurence Collette, Judith Cruz, Carla Dani, Etienne Dauzier, Arlene A. Forastiere, P. Garaud, V. Grégoire, A. Hackshaw, E. Haddad, Bruce G. Haffty, Aaron R. Hansen, Stefanie Hayoz, Jean-Claude Horiot, Branislav Jeremić, Theodore Karrison, Johannes A. Langendijk, M. Lapeyre, Éric Lartigau, Traci Leong, Quynh‐Thu Le, Patricia Lee, Freddi Lewin, Aihua Lin, Alberto Lopes, Samir Mehta, James Moon, Elizabeth Moyal, Bob‐Valéry Occéan, P. Olmi, Roberto Orecchia, Brian O’Sullivan, Jens Overgaard, Claire Petit, Harvey Quon, Giuseppe Sanguineti, Tuvana Satar, John Simes, Christian Simon, Clément Sire, S. Staar, C. Stromberger, P. Strojan, Stéphane Temam, David Thomson, A. Timochenko, Valter Torri, Vassilikì Tseroni, Jan B. Vermorken ほか 5 名 - Radiotherapy and Oncology 2021 被引用: 376

  10. Heme catabolism by tumor-associated macrophages controls metastasis formation

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Nature Immunology 2021 被引用: 124

  11. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

    著者: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 298

  12. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

    著者: , , , , , , , , , , , , , - The Lancet 2003 被引用: 1,197

  13. Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 被引用: 407

  14. HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - The Oncologist 2019 被引用: 169

  15. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alessandro Levis, Hans‐Joachim Schmoll, Franco Cavalli, Jürgen Finke, Michele Reni, Emanuele Zucca, Gerald Illerhaus - The Lancet Haematology 2016 被引用: 599

  16. Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - JNCI Journal of the National Cancer Institute 2008 被引用: 1,550

  17. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial

    著者: , , , , , , , , , , , , , , , , - ˜The œLancet. Gastroenterology & hepatology 2018 被引用: 254

  18. LBA28 The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 58

  19. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Michael Pfreundschuh, Giuseppina Cabras, F. Angrilli, Maurilio Ponzoni, Martina Deckert, Letterio S. Politi, Jürgen Finke, Michele Reni, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus - The Lancet Haematology 2017 被引用: 381

  20. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rafael Rosell, Giorgio V. Scagliotti, Lesley Seymour, Frances A. Shepherd, Richard Sylvester, Hirohito Tada, Fumihiro Tanaka, Valter Torri, David Waller, Ying Liang, for the Non-Small Cell Lung Cancer Collaborative Group - Cochrane Database of Systematic Reviews 2015 被引用: 366

  21. HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research

    著者: , , , , , , , , , , , , , , , , , , , , , - International Journal of Cancer 2016 被引用: 149

  22. Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Colorectal Cancer 2020 被引用: 104

  23. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors

    著者: , , , , , , , , , , , , , , , , - ESMO Open 2019 被引用: 212

  24. Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Reiko Imai, Lee Jeys, Robin L. Jones, Bernd Kasper, Akira Kawai, Marco Krengli, A. Leithner, I. Logowska, Javier Martín‐Broto, Diego Mazzatenta, Carlo Morosi, P. Nicolai, O.J. Norum, Shreyaskumar Patel, Nicolas Penel, Piero Picci, S. Pilotti, Stefano Redaelli, F. Ricchini, Piotr Rutkowski, S. Scheipl, Chandranath Sen, E. Tamborini, Katherine A. Thornton, Beate Timmermann, Valter Torri, P.-U. Tunn, M. Uhl, Yoshiya Yamada, Damien C. Weber, D. Vanel, Péter Varga, Carmen Vleggeert‐Lankamp, Paolo G. Casali, J. Sommer - Annals of Oncology 2017 被引用: 243